초록

A process of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with P450 metabolism, wherein the methylphenidate is d-threo-methylphenidate.

대표청구항 ▼

We claim: 1. A method of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug, said method comprising administering an effective amount of d-threo-methylphenidate to said subject. 2. The method according to claim 1, wherein the therapy is for a c

We claim: 1. A method of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug, said method comprising administering an effective amount of d-threo-methylphenidate to said subject. 2. The method according to claim 1, wherein the therapy is for a condition selected from the group consisting of depression, anxiety, epilepsy, compulsive shopping disorder, narcolepsy, insomnia and attention-deficit hyperactivity disorder. 3. The method according to claim 1, wherein said d-threo-methylphenidate and said another drug is formulated for administration to an adult patient. 4. A method for treating a patient having a condition susceptible to treatment with methylphenidate and also exhibiting or likely to exhibit other central nervous system disorders, said method comprising administering an effective amount of d-threo-methylphenidate to said patient. 5. A method for treating a patient having a condition that is susceptible to treatment with methylphenidate and concomitant therapy with another drug, said method comprising administering an effective amount of d-threo-methylphenidate to said patient. 6. The method according to claim 1, wherein said d-threo-methylphenidate is administered daily. 7. The method according to claim 1, wherein the dosage of d-threo-methylphenidate administered to said subject is 5 mg to 60 mg. 8. The method according to claim 1, wherein said d-threo-methylphenidate is in at least 95% enantiomeric excess relative to l-threo-methylphenidate. 9. The method according to claim 1, wherein said method provides for reduced side effects or reduced potential for abuse relative to racemic methylphenidate. 10. The method according to claim 4, wherein said d-threo-methylphenidate is administered daily. 11. The method according to claim 4, wherein the dosage of d-threo-methylphenidate administered to said patient is 5 mg to 60 mg. 12. The method according to claim 4, wherein said condition is attention-deficit disorder or attention-deficit hyperactivity disorder. 13. The method according to claim 4, wherein said d-threo-methylphenidate is in at least 95% enantiomeric excess relative to l-threo-methylphenidate. 14. The method according to claim 4, wherein said method provides for reduced side effects or reduced potential for abuse relative to racemic methylphenidate. 15. The method according to claim 5, wherein said d-threo-methylphenidate is administered daily. 16. The method according to claim 5, wherein the dosage of d-threo-methylphenidate administered to said patient is 5 mg to 60 mg. 17. The method according to claim 5, wherein said condition is attention-deficit disorder or attention-deficit hyperactivity disorder. 18. The method according to claim 5, wherein said d-threo-methylphenidate is in at least 95% enantiomeric excess relative to l-threo-methylphenidate. 19. The method according to claim 5, wherein said method provides for reduced side effects or reduced potential for abuse relative to racemic methylphenidate.